Breast Cancer Trial, Recruiting NCT06621459 Sponsor: University Hospital, Brest Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT06621459
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults (18 years or older)
  • People who have received a drug called abemaciclib together with hormone therapy as part of their breast cancer treatment after surgery (known as adjuvant therapy)
  • People diagnosed with a localised breast cancer that is hormone receptor positive (HR+) and HER2 non-amplified (a specific tumour type based on lab testing), where the cancer had spread to nearby lymph nodes under the arm on the same side as the tumour, meeting at least one of the following conditions:
    • 4 or more lymph nodes affected, OR
    • 1 to 3 lymph nodes affected AND the tumour was either classified as grade 3 (a higher-grade, faster-growing cancer) or measured 5 cm or larger in size

Who may not be able to join:

  • People who are under a legal protection order, such as guardianship or trusteeship
  • People who do not wish to take part in the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 0298223396

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University Hospital, Brest
Registry
ClinicalTrials.gov
Start date
26 September 2024
Est. completion
31 October 2025

Where this trial is recruiting

🇫🇷 France

Primary endpoints

the average dose of abemaciclib received over 6 months.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov